Richard joined Lumanity in 2017. He has over 12 years of experience in health outcomes statistics, systematic reviews, meta-analysis, evidence synthesis, and survival analyses. Before moving into the field of health technology assessment (HTA), Richard worked as a research scientist; he has a PhD in Molecular Biology and brings a strong understanding of fundamental biological principles in oncology and experience across a range of disease areas. He has been responsible for statistical input to HTA submissions and economic models at global and local levels, including survival, utility analysis, and a wide variety of indirect treatment comparisons. He has also worked as part of an External Assessment Group (EAG) on behalf of the National Institute for Health and Care Excellence (NICE), reviewing UK HTA submissions. More recently, Richard has played a leading role in Lumanity’s work to prepare for and deliver the strategic and analytical requirements of EU Joint Clinical Assessment.